ArticleJournal of virology2003
A naturally occurring substitution in human immunodeficiency virus Tat increases expression of the viral genome.
Article in Journal of virology, 2003. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 16 citations in OpenAlex.
- Few amino acid signatures distinguish HIV-1 subtype B pandemic and non-pandemic strains.PloS one · 2020Article
- Utilization of HIV-1 envelope V3 to identify X4- and R5-specific Tat and LTR sequence signatures.Retrovirology · 2016Article
- p53-derived host restriction of HIV-1 replication by protein kinase R-mediated Tat phosphorylation and inactivation.Journal of virology · 2015Article
- Molecular and genetic characterization of natural HIV-1 Tat Exon-1 variants from North India and their functional implications.PloS one · 2014Article
- The viral protein Tat can inhibit the establishment of HIV-1 latency.Journal of virology · 2012Article
- Analysis of infectious virus clones from two HIV-1 superinfection cases suggests that the primary strains have lower fitness.Retrovirology · 2010Article
- Establishment of HIV latency in primary CD4+ cells is due to epigenetic transcriptional silencing and P-TEFb restriction.Journal of virology · 2010Article
- CBF-1 promotes transcriptional silencing during the establishment of HIV-1 latency.The EMBO journal · 2007Article
- Site-specific amino acid frequency, fitness and the mutational landscape model of adaptation in human immunodeficiency virus type 1.Genetics · 2006Article
- Regulation of human immunodeficiency virus type 1 gene expression by clade-specific Tat proteins.Journal of virology · 2005Article
- HIV-1 clade promoters strongly influence spatial and temporal dynamics of viral replication in vivo.The Journal of clinical investigation · 2005Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution.
Funding
Abstract
A natural amino acid substitution in the human immunodeficiency virus type 1 (HIV-1) transcriptional activator Tat increases its activity and compensates for deleterious mutations elsewhere in the Tat protein. Substitution of asparagine for threonine 23 increases Tat transactivation of the HIV-1 promoter and the binding of Tat to the cellular kinase positive transcription elongation factor b (P-TEFb). Of nine other position 23 mutations tested, only the serine substitution retained wild-type activity. Correspondingly, asparagine is the most frequent amino acid at this position in HIV-1 isolates, followed by threonine and serine. Asparagine is prevalent in Tat proteins of viruses in clades A, C, and D, which are major etiologic agents of AIDS. We suggest that selection for asparagine in position 23 confers an advantage to the virus, since it can compensate for deleterious mutations in Tat. It may also support the replication of otherwise less fit drug-resistant viruses and permit the emergence of virulent strains.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.